文献速递临床试验与 GCP

五积散合生脉散治疗胃食管反流性慢性咳嗽:一项先导性随机双盲安慰剂对照试验方案

Efficacy and safety of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: protocol for a pilot, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2020-01-29

本研究为单中心、随机、双盲、安慰剂对照先导试验方案,拟纳入30例胃食管反流性慢性咳嗽患者,随机分入干预组(n=15)或安慰剂组(n=15),接受五积散合生脉散5.76 g每日三次或安慰剂治疗6周,主要结局为咳嗽日记记录的咳嗽频率与严重程度,旨在评估该合方缓解胃食管反流性慢性咳嗽的疗效与安全性。

要点

  • 五积散合生脉散颗粒5.76 g每日三次,连续6周,对照为安慰剂。
  • 主要结局为咳嗽日记记录的咳嗽频率与严重程度。
  • 纳入对象包括无胃肠道反流症状的胃食管反流性慢性咳嗽患者。

核心结论

  • 该先导试验将首次评估五积散合生脉散治疗胃食管反流性慢性咳嗽(含无胃肠道反流症状者)的疗效与安全性。
  • 研究结果将为该合方的科学应用及后续更大规模临床试验提供依据。

研究设计与样本

  • 单中心、随机、双盲、安慰剂对照先导试验方案。
  • 经过1周导入期后,30例胃食管反流性慢性咳嗽患者随机分为干预组(n=15)和安慰剂组(n=15)。
  • 干预组接受五积散合生脉散5.76 g每日三次,安慰剂组接受安慰剂,疗程6周。

关键数值与推荐

  • 主要结局指标为咳嗽日记记录的咳嗽频率与严重程度。
  • 次要结局包括咳嗽视觉模拟量表、莱斯特咳嗽问卷(韩语版)、胃肠道症状评定量表、Hull气道反流(高敏)问卷、慢性咳嗽证候辨识问卷、胃食管反流病证候辨识及安全性检测。
  • 不良事件也将被报告。

局限性

  • 本研究为先导试验,样本量较小(共30例),结果需在更大规模试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastroesophageal reflux disease (GERD) is a major cause of chronic cough. GERD-induced chronic cough is difficult to diagnose because some patients do not complain of any gastrointestinal (GI) reflux symptoms. Although chronic cough due to GERD is highly prevalent, no effective treatment is currently available, especially for GERD-related cough without GI symptoms. Because the herbal medicines Ojeok-san and Saengmaek-san can effectively treat GERD and cough, we aim to evaluate the efficacy and safety of a combination of these components for relieving chronic cough due to GERD. METHODS/DESIGN: This is a study protocol of a randomized, double-blind, placebo-controlled, single-center pilot trial. After a 1-week run-in period, a total of 30 patients with GERD-induced chronic cough will be randomly allocated to an intervention group (n = 15) or a placebo group (n = 15). Participants will receive 5.76 g of Ojeok-san plus Saengmaek-san or a placebo three times per day for 6 weeks. The primary outcome measures, which are the frequency and severity of cough, will be recorded using a cough diary. The secondary outcome measures will include a cough visual analogue scale, the Leicester Cough Questionnaire (Korean version), the Gastrointestinal Symptom Rating Scale, the Hull Airway Reflux (hypersensitivity) Questionnaire, the Pattern Identification for Chronic Cough Questionnaire, the Pattern Identification for Gastroesophageal Reflux Disease, and safety testing. Adverse events will also be reported. DISCUSSION: This will be the first clinical trial to explore the use of herbal medicines for GERD-related chronic cough, including patients without GI reflux symptoms. This study will provide useful evidence regarding the efficacy and safety of Ojeok-san plus Saengmaek-san treatment. In addition, this trial will offer a scientific basis for the combination of herbal medicines. This study will also provide important data for conducting a larger-scale clinical trial on GERD-induced chronic cough. TRIAL REGISTRATION: This trial has been registered with Clinical Research Information Service (CRIS) of South Korea (http://cris.nih.go.kr; registration number KCT0003115). Registered August 28, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bhang YH, Kim KI, Kim J, et al. Efficacy and safety of Ojeok-san plus Saengmaek-san for gastroesophageal reflux-induced chronic cough: protocol for a pilot, randomized, double-blind, placebo-controlled trial. Trials. 2020. PMID: 31996267. doi:10.1186/s13063-019-4030-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。